The most common fatal IRAE with anti–CTLA-4 therapy was colitis (70%), whereas pneumonitis (35%), hepatitis (22%), and neurotoxicity (15%) were most often seen with anti–PD-1/anti–PD-L1 therapy [57]. Here, CTLA4 is linked to colitis.